Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
65 hedge funds and large institutions have $273M invested in Strongbridge Biopharma plc. in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 9 closing their positions.
127% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 11
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
44% more capital invested
Capital invested by funds: $190M → $273M (+$82.9M)
20% more funds holding
Funds holding: 54 → 65 (+11)
1.85% more ownership
Funds ownership: 65.87% → 67.72% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$13.3M |
| 2 |
HCS
Harvest Capital Strategies
San Francisco,
California
|
+$6.18M |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$5.85M |
| 4 |
AC
Armistice Capital
New York
|
+$3.76M |
| 5 |
PM
Precept Management
Dallas,
Texas
|
+$3.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$4M |
| 2 |
TAF
Tredje AP-fonden
Se-111 91 Stockholm,
Sweden
|
-$3.29M |
| 3 |
BC
Broadfin Capital
New York
|
-$2.94M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.5M |
| 5 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$1.04M |
SBBP Hedge Fund Activity: Q1 2018 in Review
65 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q1 2018, worth a combined $273M — up 44% from $190M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new SBBP positions and 9 closed out — a net gain of 11 holders — while 25 added to existing stakes and 11 trimmed.
The largest buyer was Lyon Street Capital, adding an estimated $13.3M. The largest seller was Vivo Capital, cutting an estimated $4M.
- 65 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q1 2018, up from 54 in Q4 2017.
- Funds reported $273M of Strongbridge Biopharma plc. stock for Q1 2018, up 44% quarter-over-quarter.
- 20 funds opened new Strongbridge Biopharma plc. positions in Q1 2018 and 9 closed out, a net change of +11 holders.
- The largest Strongbridge Biopharma plc. buyer in Q1 2018 was Lyon Street Capital, an estimated $13.3M added.
- The largest Strongbridge Biopharma plc. seller in Q1 2018 was Vivo Capital, an estimated $4M sold.
Based on aggregated 13F filings for Q1 2018.